Ge Long Hui·2026-01-22 11:31Group 1 - The core point of the news is that Fosun Pharma plans to spin off its subsidiary, Fosun Antigen (Chengdu) Biopharmaceutical Co., Ltd., for a separate listing on the Hong Kong Stock Exchange [1] - The board of directors approved the proposal for the spin-off and listing on January 22, 2026 [1] - Fosun Antigen serves as the vaccine business platform for the group, focusing on research, production, and sales of vaccines using various technological platforms [1] Group 2 - After the proposed spin-off, Fosun Antigen will remain a subsidiary of the company, and its financial status and profitability will still be reflected in the consolidated financial statements of the group [2] - In the short term, the net profit (or loss) attributable to Fosun Antigen may decrease, but in the long term, its financing capabilities are expected to strengthen, enhancing operational scale, production, and R&D capabilities [2] - The spin-off is anticipated to improve the overall profitability and long-term value of the group by increasing the comprehensive competitiveness, brand recognition, and market influence of Fosun Antigen [2]